Leitlinien zur Diagnostik und Therapie bei Störungen der sexuellen Differenzierung Leitlinien der Deutschen Gesellschaft für Urologie

Not Available Not Available

DOI: https://doi.org/10.1007/s001200050013

Der Urologe A

Abstract:

What problem does this paper attempt to address?

Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid

A. Carcas,F. Abad‐Santos,Jesús M de Rosendo,J. R. Anderica Frías

DOI: https://doi.org/10.1177/106002809603000208

1996-02-01

Abstract:OBJECTIVE: To report nimodipine concentrations in breast milk and cerebrospinal fluid (CSF) of a lactating woman who was given the drug to prevent a vascular spasm secondary to angiographic examination. METHODS: A 36-year-old woman received a total dose of nimodipine 46 mg iv over 24 hours. She extracted milk when she noted mammary tightness, and blood samples were taken simultaneously by venipuncture in the arm contralateral to that of the nimodipine infusion. A CSF sample also was taken in a diagnostic lumbar puncture. RESULTS: Nimodipine concentration in milk was much lower than that in serum, with a milk/serum ratio of 0.06–0.15. The CSF/serum ratio was 0.01. We estimate that the infant would have received between 0.008% and 0.092% of the weight-adjusted dose that was administered to the mother if the baby had been nursed. CONCLUSIONS: Nimodipine is transferred to human milk in a lower proportion than are other calcium-channel blockers. These results suggest that treating the mother with nimodipine would entail no risk to the nursing infant.
DSA type secure interactive batch verification protocols

L. Harn

DOI: https://doi.org/10.1049/EL:19950203

1995-02-16

Abstract:The author proposes some DSA type secure interactive batch verification protocols, where the signer generates n signatures through interactions with the verifier, and the verifier validates all these n signatures.
2-[3-(1,1-Dimethylethyl)-5-methoxyphenyloxazolo[4,5-b]pyridine, a new topical antiinflammatory and analgesic compound lacking systemic activity and gastric side effects.

R. Bonney,B. J. Olson,T. Bach,G. Beveridge,M. Goldenberg,C. O. Gitterman,J. Humes,A. Y. Lu,H. Hucker,H. Dougherty

Abstract:The substituted oxazolopyridine 2-[3-(1,1-dimethylethyl)-5-methoxyphenyl]oxazolo[4,5-b]pyridine (OZP) inhibits phorbol myristate acetate-induced increases in vascular permeability and neutrophil accumulation in rat ears with ED50 of 253 and 200 micrograms, respectively. This compound is as potent as indomethacin to inhibit UV-induced erythema in guinea pig skin and is an effective analgesic when applied topically to the rat footpad in the yeast hyperalgesia model. OZP is a cyclooxygenase inhibitor with an IC50 of 0.06 mumol/l and inhibits prostaglandin E2, but not leukotriene C4 synthesis, by mouse peritoneal macrophages. This compound is inactive in the carrageenan paw edema assay at 90 mg/kg when administered orally or intraperitoneally, but is effective when injected into the paw. OZP is not a contact allergen and does not cause gastric irritation in rats at doses up to 180 mg/kg orally. OZP is rapidly metabolized by rat liver microsomes in a concentration and time dependent manner. Furthermore, when administered orally, OZP is cleared rapidly in rats with plasma levels being detected only at 5 and 30 min following a 2 mg/kg dose. There was no drug in the gastrointestinal tract of rats 3 h after an oral dose. Thus, this compound appears to be a new, potent and safe topical antiinflammatory and an analgesic agent lacking systemic effects.
The enigma of sclera-specific autoimmunity in scleritis

Daphne P.C. Vergouwen,Adriaan A. van Beek,Joeri de Hoog,Joke H. de Boer,Leonoor I. Los,Marlies Gijs,Roel J. Erckens,Rob M. Verdijk,Geert W. Haasnoot,Dave L. Roelen,Aniki Rothova,Johan Rönnelid,Josianne C. Ten Berge,Marco W.J. Schreurs

DOI: https://doi.org/10.1016/j.jaut.2024.103178

IF: 14.511

2024-02-19

Journal of Autoimmunity

Abstract:Scleritis is a severe and painful ophthalmic disorder, in which a pathogenic role for collagen-directed autoimmunity was repeatedly suggested. We evaluated the presence of sclera-specific antibodies in a large cohort of patients with non-infectious scleritis. Therefore, we prospectively collected serum samples from 121 patients with non-infectious scleritis in a multicenter cohort study in the Netherlands. In addition, healthy (n = 39) and uveitis controls (n = 48) were included. Serum samples were tested for anti-native human type II collagen antibodies using a validated enzyme-linked immunosorbent assay (ELISA). Further, sclera-specific antibodies were determined using indirect immunofluorescence (IIF) on primate retinal/scleral cryosections. Lastly, human leukocyte antigen (HLA) typing was performed in 111 patients with scleritis. Anti-type II collagen antibodies were found in 13% of scleritis patients, in 10% of healthy controls and in 11% of uveitis controls (p = 0.91). A specific reaction to scleral nerve tissue on IIF was observed in 33% of patients with scleritis, which was higher than in healthy controls (11%; p = 0.01), but similar to uveitis controls (25%; p = 0.36). Reactivity to the scleral nerve tissue was significantly associated with earlier onset of scleritis (48 versus 56 years; p < 0.001), bilateral involvement (65% versus 42%; p = 0.01), and less frequent development of scleral necrosis (5% versus 22%; p = 0.02). HLA-B27 was found to be twice as prevalent in patients with scleritis (15.3%) compared to a healthy population (7.2%). In conclusion, scleral nerve autoantibody reactivity was more common in scleritis and uveitis patients in contrast to healthy controls. Further research is needed to characterize these scleral-nerve directed antibodies and assess their clinical value.

immunology
Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review

Tessalyn Morrison,Moriah Gottman,Toan Do,James T Rosenbaum,Daniela Ghetie,Marcia Friedman,James T. Rosenbaum

DOI: https://doi.org/10.3899/jrheum.2023-0788

2024-02-01

The Journal of Rheumatology

Abstract:Objective Scleritis may be idiopathic or caused by trauma, infections, or an immune-mediated disease (IMD). Our study aimed to understand the relationship between scleritis and IMD, including presenting characteristics, serologies, and treatment course. Understanding these associations may allow clinicians to risk-stratify patients and predict their clinical and treatment course. Methods We conducted a retrospective chart review of 341 patients with scleritis seen at a tertiary care center between January 1, 2005, and December 31, 2020. Demographics, scleritis characteristics, treatment response, recurrence, and serologic data were compared among patients with idiopathic and IMD-associated scleritis. Results Among patients with scleritis seen, 145 patients (43%) had an associated IMD, most commonly rheumatoid arthritis (RA; 39%), vasculitis (21%), or inflammatory bowel disease (14%). In most cases, the IMD diagnosis predated the scleritis presentation (63%), though vasculitis cases were more likely to develop during or after scleritis episodes. There were no significant differences in demographics or treatment failures among patients with scleritis with and without associated IMDs. Patients with IMDs were more likely to have a recurrence of scleritis (62% vs 49%, P = 0.02). Conclusion At our ophthalmology center, 43% of patients with scleritis had an associated IMD, and most patients with an IMD were symptomatic from this disease prior to scleritis presentation. RA was the most commonly associated condition and typically predated the scleritis, whereas vasculitis was more likely diagnosed during or after the scleritis episode. Scleritis among patients with IMD is more likely to recur compared to scleritis that is idiopathic.

rheumatology
New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Claudia Fabiani,Jurgen Sota,Maite Sainz-de-la-Maza,Laura Pelegrín,Giacomo Emmi,Giuseppe Lopalco,Florenzo Iannone,Lorenzo Vannozzi,Silvana Guerriero,Maria Chiara Gelmi,Donato Rigante,Gian Marco Tosi,José Hernández-Rodríguez,Luca Cantarini

DOI: https://doi.org/10.1155/2020/8294560

2020-01-17

Abstract:Objective: To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-) α inhibitors, in the management of noninfectious refractory scleritis, either idiopathic or associated with systemic immune-mediated disorders. Patients and Methods. This is a retrospective study assessing the efficacy of several biologic agents (rituximab, anakinra, tocilizumab, and abatacept) and the small molecule tofacitinib in the treatment of scleritis through assessment of scleral inflammation and relapses, as well as treatment impact on best-corrected visual acuity (BCVA) and safety profile. Results: Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (p = 0.002) and from baseline to the last follow-up visit (p = 0.002). Scleritis relapses significantly decreased between the 12 months preceding and following biologic therapy (p = 0.007). No differences regarding BCVA were observed (p = 0.67). Regarding adverse events, only one patient developed pneumonia and septic shock under rituximab treatment. Conclusions: Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses.
Scleritis: Differentiating infectious from non-infectious entities

Somasheila I Murthy,Swapnali Sabhapandit,S Balamurugan,Pranesh Subramaniam,Maite Sainz-de-la-Maza,Manisha Agarwal,Carlos Parvesio

DOI: https://doi.org/10.4103/ijo.IJO_2032_20

Abstract:Scleritis is a rare painful ocular disorder, associated with severe ocular pain and tissue destruction. Although a majority of these cases are immune mediated and at least half of these are associated with systemic immune-mediated diseases, a smaller minority are due to infections of the sclera. The two conditions closely mimic each other, and a thorough knowledge of the subtle differences is necessary in order to reach a timely diagnosis. Diagnostic delay can lead to a poor outcome both due to the destruction caused by the uncontrolled infection and also due to propagation of the infection with the use of corticosteroids which may have been started for presumed immune mediated scleritis. In this review, we present the clinical features, etiological agents, and the differentiating features between immune and infectious scleritis. We also present diagnostic and management guidelines for managing scleral infection.
Hepatic veno-occlusive disease related to tacrolimus after pancreas transplantation.

Shin-E Wang,Y. Shyr,R. Lee

DOI: https://doi.org/10.1016/j.jcma.2013.03.001

2013-06-01

Journal of the Chinese Medical Association

Abstract:
Adjunctive Rifampin Is Crucial to Optimizing Daptomycin Efficacy against Rabbit Prosthetic Joint Infection Due to Methicillin-Resistant Staphylococcus aureus

A. Saleh-Mghir,C. Muller-Serieys,A. Dinh,L. Massias,A. Crémieux

DOI: https://doi.org/10.1128/AAC.00675-11

IF: 5.938

2011-08-08

Antimicrobial Agents and Chemotherapy

Abstract:ABSTRACT Daptomycin is an attractive option for treating prosthetic joint infection, but the 6-mg/kg of body weight/day dose was linked to clinical failure and emergence of resistance. Using a methicillin-resistant Staphylococcus aureus (MRSA) knee prosthesis infection in rabbits, we studied the efficacies of high-dose daptomycin (22 mg/kg given intravenously [i.v.] once daily [o.d.]; equivalent to 8 mg/kg/day in humans) or vancomycin (60 mg/kg given intramuscularly [i.m.] twice daily [b.i.d.]), both either alone or with adjunctive rifampin (10 mg/kg i.m. b.i.d.). After partial knee replacement with a silicone implant, 107 MRSA CFU was injected into the knees. Treatment started 7 days postinoculation and lasted 7 days. Positive cultures were screened for the emergence of mutant strains, defined as having 3-fold-increased MICs. Although in vivo mean log10 CFU/g of daptomycin-treated (4.23 ± 1.44; n = 12) or vancomycin-treated (4.63 ± 1.08; n = 12) crushed bone was significantly lower than that of controls (5.93 ± 1.15; n = 9) (P < 0.01), neither treatment sterilized bone (2/12 and 0/12 rabbits with sterile bone, respectively). Daptomycin mutant strains were found in 6/12, 3/12, and 2/9 daptomycin-treated, vancomycin-treated, and control rabbits, respectively; no resistant strains emerged (MIC was always <1 mg/liter). Adjunctive rifampin with daptomycin (1.47 ± 0.04 CFU/g of bone [detection threshold]; 11/11 sterile bones) or vancomycin (1.5 ± 0.12 CFU/g of bone; 6/8 sterile bones) was significantly more effective than monotherapy (P < 0.01) and prevented the emergence of daptomycin mutant strains. In this MRSA joint prosthesis infection model, combining rifampin with daptomycin was highly effective. Daptomycin mutant strains were isolated in vivo even without treatment, but adjunctive rifampin prevented this phenomenon, previously found after monotherapy in humans.
Pathophysiology of systemic sclerosis (scleroderma)

Ann‐Helen Rosendahl,Katrin Schönborn,Thomas Krieg

DOI: https://doi.org/10.1002/kjm2.12505

2022-03-01

The Kaohsiung Journal of Medical Sciences

Abstract:Systemic sclerosis (scleroderma) is an autoimmune-triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction. Based on a predisposing genetic background, an altered balance of the acquired and the innate immune system leads to the release of many cytokines and chemokines as well as autoantibodies, which induce the activation of fibroblasts with the formation of myofibroblasts and the deposition of a stiff and rigid connective tissue. A curative treatment is still not available but remarkable progress has been made in the management of organ complications. In addition, several breakthroughs in the pathophysiology have led to new therapeutic concepts. Based on these, many new compounds have been developed during the last years, which target these different pathways and offer specific therapeutic approaches.
Management of Scleritis in Older Adults

Laura Butler,Oren Tomkins-Netzer,Or Reiser,Rachael L Niederer

DOI: https://doi.org/10.1007/s40266-024-01105-0

2024-03-06

Drugs & Aging

Abstract:Scleritis, an inflammatory disease of the eye affecting scleral tissue, presents unique challenges in the older adult population. Unlike their younger counterparts, older individuals manifest a distinct spectrum of the disease with different underlying etiologies, co-morbidities, altered immune function, and an increased risk of systemic side effects from medication choices. Addressing these complexities necessitates a comprehensive and multidisciplinary approach. Treatment of choice will depend on any underlying cause but generally involves non-steroidal anti-inflammatory drugs, systemic or local corticosteroids, and potentially disease-modifying anti-rheumatic drugs. Utilization of these therapeutic agents in older adults warrants careful consideration because of their potential side-effect profiles. This article critically examines the specific concerns for the use of these drugs in older patients and reviews the existing literature on their use in this specific cohort.

pharmacology & pharmacy,geriatrics & gerontology,gerontology
Autoimmunity in uveitis

Josianne C Ten Berge,Marco W J Schreurs,Paul L A van Daele,Aniki Rothova

DOI: https://doi.org/10.1111/aos.13652

Abstract:Purpose: Recent insights into the pathogenesis of immune-mediated diseases proposed a new classification, which includes autoimmune and auto-inflammatory diseases. The prevalence of specific autoimmune and auto-inflammatory diseases in uveitis and/or scleritis is not yet known. In this study, we examine the presence of systemic immune-mediated diseases in patients with uveitis and/or scleritis and put a special emphasis on autoimmune disorders by reporting on their clinical manifestations and visual prognosis. Methods: In this retrospective study, we reviewed data of 1327 patients presenting with uveitis and/or scleritis between January 2010 and July 2016 at the Erasmus Medical Center, Rotterdam, the Netherlands. All patients with noninfectious uveitis and/or scleritis were classified according to novel criteria for immune-mediated diseases. Various clinical data, including visual acuity (VA), of patients with uveitis of autoimmune origin were registered during 5-year follow-up. Results: The origin of uveitis was in 5% (62/1327) autoimmune, in 15% (197/1327) auto-inflammatory and in 14% (180/1327) mixed autoimmune/auto-inflammatory. Patients with classical autoimmune connective tissue disease (N = 17) suffered mostly from rheumatoid arthritis and granulomatosis with polyangiitis and exhibited predominantly scleritis (53%). After 5 years of follow-up, none of the eyes of these patients developed legal blindness (VA of <0.1). The VA in patients with uveitis associated with autoimmune neuro-ophthalmological diseases (multiple sclerosis and neuromyelitis optica; N = 27) remained stable over time. Conclusion: Uveitis and scleritis of autoimmune origin were observed in 5% of the total series. The term autoimmune uveitis should not be used as a synonym for intraocular inflammation of noninfectious origin.
Posterior Scleritis: A Case Report and Literature Review of the Management of the Condition

Raheem Robertson,Fawwad A Ansari,Stefan Gafoor,Osahon N Idolor,Dominic Amakye

DOI: https://doi.org/10.7759/cureus.61537

2024-06-02

Cureus

Abstract:Posterior scleritis is a rare inflammatory eye condition affecting the posterior segments of the sclera and is more prevalent in females. Its clinical presentation, often nonspecific, includes ocular pain, headache, and vision loss. Misdiagnosis is common due to a lack of specific symptoms posing a potential threat to vision. The etiology is often tied to rheumatic diseases, such as rheumatoid arthritis (RA), systemic erythematous lupus (SLE), and anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis. Posterior scleritis poses diagnostic challenges, mimicking many other ocular conditions, hence necessitating a thorough clinical eye exam. Laboratory studies, including inflammatory markers and markers of rheumatic diseases, may identify underlying systemic diseases. Imaging, including B-scan ultrasound and magnetic resonance imaging (MRI), aids in accurate diagnosis. Treatment involves non-steroidal anti-inflammatory drugs (NSAID), as well as topical corticosteroids for mild disease and systemic corticosteroids for severe disease. Biologic therapy has become increasingly significant for refractory cases. A multidisciplinary approach involving ophthalmology and rheumatology is crucial in the management of this potential sight-threatening disease. This case report highlights a 46-year-old woman with a history of RA-associated posterior scleritis.
Update on the pathophysiology and treatment of primary Sjögren syndrome

Chiara Baldini,Giovanni Fulvio,Gaetano La Rocca,Francesco Ferro

DOI: https://doi.org/10.1038/s41584-024-01135-3

Abstract:Sjögren syndrome or Sjögren disease is a chronic form of autoimmune epithelitis characterized by lymphocytic infiltration of the exocrine glands, particularly the salivary and lacrimal glands, leading to progressive glandular dysfunction and subsequent xerostomia and xerophthalmia. Other common manifestations include pain and fatigue, various systemic manifestations and non-Hodgkin's lymphoma. Sjögren syndrome is therefore a complex and disabling disease associated with a reduced quality of life and with considerable long-term damage. Most of the available treatments are merely symptomatic with limited efficacy in both preventing glandular damage and suppressing systemic disease activity. In the past 10 years, great progress has been made in understanding the pathophysiology of Sjögren syndrome, opening new avenues towards a more targeted and individualized therapeutic approach to the disease. Indeed, several randomized controlled trials have just been completed or are poised to commence evaluating the effectiveness of novel drugs targeting both innate and adaptive immune pathways, including pro-inflammatory cytokines, the type I interferon system, B cell activation, B cell and T cell co-stimulation pathway, and ectopic germinal centre formation. Novel clinical trials are also ongoing exploring various targeted approaches (that is, IgG recycling inhibition, nuclease therapy and CAR-T cell therapy) for Sjögren syndrome.
Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis

Marco Binda,Beatrice Moccaldi,Giovanni Civieri,Anna Cuberli,Andrea Doria,Francesco Tona,Elisabetta Zanatta

DOI: https://doi.org/10.3390/ijms25042299

IF: 5.6

2024-02-15

International Journal of Molecular Sciences

Abstract:Systemic sclerosis (SSc) is a multifaceted connective tissue disease whose aetiology remains largely unknown. Autoimmunity is thought to play a pivotal role in the development of the disease, but the direct pathogenic role of SSc-specific autoantibodies remains to be established. The recent discovery of functional antibodies targeting G-protein-coupled receptors (GPCRs), whose presence has been demonstrated in different autoimmune conditions, has shed some light on SSc pathogenesis. These antibodies bind to GPCRs expressed on immune and non-immune cells as their endogenous ligands, exerting either a stimulatory or inhibitory effect on corresponding intracellular pathways. Growing evidence suggests that, in SSc, the presence of anti-GPCRs antibodies correlates with specific clinical manifestations. Autoantibodies targeting endothelin receptor type A (ETAR) and angiotensin type 1 receptor (AT1R) are associated with severe vasculopathic SSc-related manifestations, while anti-C-X-C motif chemokine receptors (CXCR) antibodies seem to be predictive of interstitial lung involvement; anti-muscarinic-3 acetylcholine receptor (M3R) antibodies have been found in patients with severe gastrointestinal involvement and anti-protease-activated receptor 1 (PAR1) antibodies have been detected in patients experiencing scleroderma renal crisis. This review aims to clarify the potential pathogenetic significance of GPCR-targeting autoantibodies in SSc, focusing on their associations with the different clinical manifestations of scleroderma. An extensive examination of functional autoimmunity targeting GPCRs might provide valuable insights into the underlying pathogenetic mechanisms of SSc, thus enabling the development of novel therapeutic strategies tailored to target GPCR-mediated pathways.

biochemistry & molecular biology,chemistry, multidisciplinary
Immunologic basis for development of keratoconjunctivitis sicca in systemic autoimmune diseases: Role of innate immune sensors

Michael E. Stern,Argyrios N. Theofilopoulos,Philipp Steven,Jerry Y. Niederkorn,Robert Fox,Margarita Calonge,Christof Scheid,Stephen C. Pflugfelder

DOI: https://doi.org/10.1016/j.jtos.2024.02.003

IF: 6.268

2024-02-23

The Ocular Surface

Abstract:The literature is filled with citations reporting an increased incidence of chronic dry eye disease, also known as keratoconjunctivitis sicca, in patients with systemic autoimmune diseases such as rheumatoid arthritis, Sjögren's Syndrome, systemic sclerosis and lupus. As the most environmentally exposed mucosal surface of the body, the conjunctiva constantly responds to environmental challenges which are typically self limited, but when persistent and unresolved may provoke pathogenic innate and adaptive immune reactions. Our understanding of the pathophysiological mechanisms by which systemic autoimmune diseases cause dry eye inducing ocular surface inflammation continues to evolve. Conjunctival immune tone responds to self or foreign danger signals (including desiccating stress) on the ocular surface with an initial non-specific innate inflammatory response. If unchecked, this can lead to activation of dendritic cells that present antigen and prime T and B cells resulting in an adaptive immune reaction. These reactions generally resolve, but dysfunctional, hyper-responsive immune cells found in systemic autoimmune diseases that are recruited to the ocular surface can amplify inflammatory stress responses in the ocular surface and glandular tissues and result in autoimmune reactions that disrupt tear stability and lead to chronic dry eye disease. We here propose that unique features of the ocular surface immune system and the impact of systemic immune dysregulation in autoimmune diseases, can predispose to development of dry eye disease, and exacerbate severity of existing dry eye.

ophthalmology
Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population‐Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune‐Mediated Inflammatory Disease

Tasanee Braithwaite,Nicola J. Adderley,Anuradhaa Subramanian,James Galloway,John H. Kempen,Krishna Gokhale,Andrew P. Cope,Andrew D. Dick,Krishnarajah Nirantharakumar,Alastair K. Denniston,John H. Kempen,Alastair K. Denniston

DOI: https://doi.org/10.1002/art.41709

2021-06-06

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To estimate 22‐year trends in scleritis prevalence and incidence and associations with infectious/immune‐mediated inflammatory diseases (I‐IMIDs) in the United Kingdom (UK).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Retrospective cross‐sectional and population cohort study (1997‐2018) included 10,939,823 patients (n=2946 incident scleritis cases) in The Health Improvement Network (THIN), a nationally‐representative primary care records database. Case‐control and cohort study (1995‐2019) included 3005 incident scleritis cases and 12,020 control patients matched by age, sex, region and Townsend Deprivation Index (TDI). We adjusted Poisson, Logistic and Cox proportional hazard multivariable models by age, sex, TDI, race/ethnicity, smoking, nation and body mass index category. Estimates include 95% confidence intervals.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Scleritis incidence rates declined from 4·23(2·16‐6·31) to 2·79(2·19‐3·39) per 100,000 person‐years between 1997 and 2018. Prevalence was 93·62(90·17‐97·07)/100,000 people in 2018 (61,650 UK patients). Amongst 2946 incident scleritis patients, 62·2%(n=1831) were female, mean age was 44·9(SD17·6, range 1‐93) years and 88·8%(n=1257) were White. Higher risk of incident scleritis was associated with female sex (adjusted incidence rate ratio [aIRR]=1·54, 1·43‐1·66,p<0.001), Black (aIRR=1·52, 1·14‐2·01,p=0.004) or South Asian race/ethnicity (aIRR=1·50, 1·19‐1·90,p<0.001) versus White, and older age (peak aIRR=4·95, 3·99‐6·14,p<0.001 for ages 51‐60 years versus ≤10 years). Compared to controls, scleritis patients had 2‐fold increased risk of prior I‐IMID diagnosis (p<0.001, 17 I‐IMIDs) and significantly increased risk of subsequent diagnosis of 13 I‐IMIDs. Strongest associations included granulomatosis with polyangiitis, Behçet's disease, and Sjögren's syndrome.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>Over 1997‐2018 the UK incidence of scleritis declined from 4·23 to 2·79/100,000 persons/year. Incident scleritis was associated with 19 I‐IMIDs, providing data for rational investigation and cross‐specialty engagement.</p></section>

rheumatology
[Sjögren's disease: From pathophysiology to treatment]

Xavier Mariette

DOI: https://doi.org/10.1051/jbio/2024003

Abstract:Sjögren's disease (SjD) is a systemic autoimmune disorder characterized by a triad of key symptoms affecting almost all patients (salivary and lacrimal dryness, pain and fatigue) and extra-glandular systemic involvement affecting one to two-thirds of patients. Over the past decade, knowledge of the epidemiology, classification criteria, assessment of systemic activity and symptoms presented by patients has grown. In addition, advances in understanding the pathophysiology of SjD have enabled a more targeted therapeutic approach. Current management of SjD is based on EULAR treatment guidelines. But since these recommendations, new drugs targeting specific pathophysiological pathways of the disease, and essentially B lymphocyte activation, have shown efficacy in phase 2 trials. In this review, we will summarize the available evidence on systemic therapies, including: 1. advances in outcome assessment, 2. current evidence on targeted disease-modifying therapies and biologic drugs targeting primarily B lymphocytes, 3. an overview of promising drugs being tested in ongoing trials.
Immunopathogenesis of systemic lupus erythematosus: An update

Laurent Arnaud,François Chasset,Thierry Martin

DOI: https://doi.org/10.1016/j.autrev.2024.103648

Abstract:Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by dysregulated immune responses leading to widespread inflammation and damage in various organs. Environmental factors such as infections, hormonal influences and exposure to ultraviolet light can trigger the disease in genetically predisposed individuals. Genome-wide association studies have identified over 100 susceptibility loci linked to immune regulation, interferon (IFN) signaling and antigen presentation in SLE. In addition, rare cases of monogenic lupus have been instrumental in understanding critical underlying disease mechanisms. Several immunological abnormalities contribute to the loss of self-tolerance and the perpetuation of autoimmune responses in SLE. In particular, defective clearance of apoptotic cells due to defective phagocytosis and complement activation leads to accumulation of self-antigens. Dysregulated innate immune responses activate the adaptive immune system, amplifying the inflammatory response with an important role for type I IFNs. Abnormalities in B cell development and activation lead to the production of autoreactive antibodies, forming immune complexes that cause tissue damage. Similarly, disturbances in T-cell compartments, altered regulatory T-cell functions and altered cytokine production, particularly IFN-α, contribute to tissue damage. Understanding of the immunopathogenesis of SLE is evolving rapidly, with ongoing research identifying new molecular pathways and potential therapeutic targets. Future classifications of SLE are likely to be based on underlying biological pathways rather than clinical and serological signs alone. This review aims to provide a detailed update on the most recent findings regarding the immunopathogenesis of SLE, focusing on the variability of biological pathways and the implications for future therapeutic strategies, in particular chimeric antigen receptor T (CAR T) cells.
Current Concepts on the Pathogenesis of Systemic Sclerosis

Marie Elise Truchetet,Nicolò C. Brembilla,Carlo Chizzolini

DOI: https://doi.org/10.1007/s12016-021-08889-8

2021-09-06

Abstract:Abstract From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical presentation and course are highly heterogenous and life expectancy variably affected mostly dependent on lung and heart involvement. SSc touches more women than men with differences in disease severity and environmental exposure. Pathogenetic events originate from altered homeostasis favored by genetic predisposition, environmental cues and a variety of endogenous and exogenous triggers. Epigenetic modifications modulate SSc pathogenesis which strikingly associate profound immune-inflammatory dysregulation, abnormal endothelial cell behavior, and cell trans-differentiation into myofibroblasts. SSc myofibroblasts show enhanced survival and enhanced extracellular matrix deposition presenting altered structure and altered physicochemical properties. Additional cell types of likely pathogenic importance are pericytes, platelets, and keratinocytes in conjunction with their relationship with vessel wall cells and fibroblasts. In SSc, the profibrotic milieu is favored by cell signaling initiated in the one hand by transforming growth factor-beta and related cytokines and in the other hand by innate and adaptive type 2 immune responses. Radical oxygen species and invariant receptors sensing danger participate to altered cell behavior. Conventional and SSc-specific T cell subsets modulate both fibroblasts as well as endothelial cell dysfunction. Beside autoantibodies directed against ubiquitous antigens important for enhanced clinical classification, antigen-specific agonistic autoantibodies may have a pathogenic role. Recent studies based on single-cell RNAseq and multi-omics approaches are revealing unforeseen heterogeneity in SSc cell differentiation and functional states. Advances in system biology applied to the wealth of data generated by unbiased screening are allowing to subgroup patients based on distinct pathogenic mechanisms. Deciphering heterogeneity in pathogenic mechanisms will pave the way to highly needed personalized therapeutic approaches.

immunology,allergy

Leitlinien zur Diagnostik und Therapie bei Störungen der sexuellen Differenzierung Leitlinien der Deutschen Gesellschaft für Urologie

Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid

DSA type secure interactive batch verification protocols

2-[3-(1,1-Dimethylethyl)-5-methoxyphenyloxazolo[4,5-b]pyridine, a new topical antiinflammatory and analgesic compound lacking systemic activity and gastric side effects.

The enigma of sclera-specific autoimmunity in scleritis

Scleritis and Development of Immune-Mediated Disease: A Retrospective Chart Review

New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy

Scleritis: Differentiating infectious from non-infectious entities

Hepatic veno-occlusive disease related to tacrolimus after pancreas transplantation.

Adjunctive Rifampin Is Crucial to Optimizing Daptomycin Efficacy against Rabbit Prosthetic Joint Infection Due to Methicillin-Resistant Staphylococcus aureus

Pathophysiology of systemic sclerosis (scleroderma)

Management of Scleritis in Older Adults

Autoimmunity in uveitis

Posterior Scleritis: A Case Report and Literature Review of the Management of the Condition

Update on the pathophysiology and treatment of primary Sjögren syndrome

Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis

Immunologic basis for development of keratoconjunctivitis sicca in systemic autoimmune diseases: Role of innate immune sensors

Epidemiology of Scleritis in the United Kingdom From 1997 to 2018: Population‐Based Analysis of 11 Million Patients and Association Between Scleritis and Infectious and Immune‐Mediated Inflammatory Disease

[Sjögren's disease: From pathophysiology to treatment]

Immunopathogenesis of systemic lupus erythematosus: An update

Current Concepts on the Pathogenesis of Systemic Sclerosis